Sayan Mullick Chowdhury
Overview
Explore the profile of Sayan Mullick Chowdhury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdhury S, Hong F, Rolfo C, Li Z, He K, Wesolowski R, et al.
Biology (Basel)
. 2025 Feb;
14(2).
PMID: 40001982
Canopy FGF signaling regulator 2 (CNPY2) has emerged as a crucial player in cancer development by promoting cell proliferation, tissue repair, and angiogenesis. This review synthesizes the current understanding of...
2.
Chowdhury S, Bhatta S, Voorhees T, Annunzio K, Bond D, Sawalha Y, et al.
J Hematol Oncol
. 2025 Jan;
18(1):4.
PMID: 39757235
Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust...
3.
Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo T, et al.
Blood Adv
. 2024 Mar;
8(10):2592-2599.
PMID: 38531057
Chimeric antigen receptor (CAR) T-cell (CAR-T) immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of the convergence of race...
4.
Rezazadeh A, Szabo A, Khurana A, Inwards D, Lunning M, Bartlett N, et al.
Haematologica
. 2023 Oct;
109(5):1439-1444.
PMID: 37855051
Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT...
5.
Jain N, Mamgain M, Chowdhury S, Jindal U, Sharma I, Sehgal L, et al.
J Hematol Oncol
. 2023 Aug;
16(1):99.
PMID: 37626420
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2-6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of...
6.
Epperla N, Welkie R, Torka P, Shouse G, Karmali R, Shea L, et al.
J Hematol Oncol
. 2023 May;
16(1):49.
PMID: 37158890
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not...
7.
McKenna M, Epperla N, Ghobadi A, Liu J, Lazaryan A, Ibrahim U, et al.
Br J Haematol
. 2023 May;
202(2):248-255.
PMID: 37129856
The use of CD19 chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory solid organ transplantation (SOT)-related post-transplant lymphoproliferative disorder (PTLD) is not well studied. We conducted a multicentre, retrospective analysis...
8.
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, et al.
Blood Adv
. 2022 Oct;
7(1):88-91.
PMID: 36269847
No abstract available.
9.
Epperla N, Reljic T, Chowdhury S, Ferreri A, Kumar A, Hamadani M
Hematol Oncol
. 2022 Oct;
41(1):88-96.
PMID: 36192141
The management of newly diagnosed primary central nervous system lymphoma (PCNSL) includes administration of high-dose methotrexate based regimens followed by consolidation therapy to minimize the risk of relapse. However, the...
10.
Zurko J, Nizamuddin I, Epperla N, David K, Cohen J, Moyo T, et al.
Blood Adv
. 2022 Sep;
7(12):2657-2669.
PMID: 36094847
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory...